Abstract |
Mice suffering from melanoma can be cured by treatment with a recombinant antibody- lymphotoxin-alpha fusion protein. In order to characterize the involvement of T cells in this syngeneic tumor model, the T cell receptor repertoire was analyzed both quantitatively and qualitatively. In this connection, quantitative analysis of the T cell receptors displayed only a modest overexpression in some of the variable beta chain families over the course of therapy. Clonotypic mapping, however, revealed a marked increase in the number of clonally expanded T cells among the tumor-infiltrating T cells, suggesting a specific activation.
|
Authors | David Schrama, Per thor Straten, Eva-Bettina Bröcker, Ralph A Reisfeld, Jürgen C Becker |
Journal | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
(Recent Results Cancer Res)
Vol. 160
Pg. 185-94
( 2002)
ISSN: 0080-0015 [Print] Germany |
PMID | 12079213
(Publication Type: Journal Article)
|
Chemical References |
- Cytokines
- Lymphotoxin-alpha
- Recombinant Fusion Proteins
|
Topics |
- Animals
- Clone Cells
- Cytokines
(therapeutic use)
- Lymphotoxin-alpha
(therapeutic use)
- Melanoma, Experimental
(therapy)
- Mice
- Mice, Inbred C57BL
- Recombinant Fusion Proteins
(therapeutic use)
- Reverse Transcriptase Polymerase Chain Reaction
- T-Lymphocytes
(immunology)
- Tumor Cells, Cultured
|